-+ 0.00%
-+ 0.00%
-+ 0.00%

argenx Advances Neuromuscular Pipeline With First-in-Human ARGX-119 Data And Ongoing Label Expansion For Ocular And Seronegative MG

Benzinga·04/08/2025 05:52:04
Listen to the news
  • ADAPT-NXT data demonstrate consistent, sustained disease control across dosing schedules, further supporting individualized VYVGART dosing for gMG patients
  • ADHERE+ oral presentation features long-term CIDP data demonstrating VYVGART Hytrulo's durable efficacy, sustained functional improvements and favorable safety profile
  • argenx continues to advance a robust neuromuscular pipeline of clinical candidates; first-in-human data of ARGX-119 (MuSK agonist) support pipeline-in-a-product development plan